1. Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013 Oct; 6: 139-51. DOI: 10.2147/IBPC.S33984 [ DOI] [ PubMed] 2. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000 Sep; 36(3): 312-18. DOI: 10.1161/01.hyp.36.3.312 [ DOI] [ PubMed] 3. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008 Jan; 75(2): 346-59. DOI: 10.1016/j.bcp.2007.07.004 [ DOI] [ PubMed] 4. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994 Dec; 94(6): 2493-503. DOI: 10.1172/JCI117619 [ DOI] [ PubMed] 5. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension. Am J Hypertens. 2004 Mar; 17(3): 273-76. DOI: 10.1016/j.amjhyper.2003.11.007 [ DOI] [ PubMed] 6. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GYH. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens. 2004 Sep; 17(9): 770-74. DOI: 10.1016/j.amjhyper.2004.06.023 [ DOI] [ PubMed] 7. Gruszka K, Rajzer M, Drożdż T, Wojciechowska W, Pizoń T, Migacz-Gruszka K, et al. Selected matrix metalloproteinases activity and hypertension-mediated organ damage in relation to uric acid serum level. Cardiol J. 2019 Apr. DOI: 10.5603/CJ.a2019.0033 Online ahead of print [ DOI] [ PubMed] 8. Johnson JL. Metalloproteinases in atherosclerosis. Eur J Pharmacol. 2017 Dec; 816: 93-106. DOI: 10.1016/j.ejphar.2017.09.007 [ DOI] [ PubMed] 9. Matsui K, Takano Y, Yu ZX, Hi JES, Stetler-Stevenson WG, Travis WD, et al. Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy. Pathology - Research and Practice. 2002; 198(6): 403-12. DOI: 10.1078/0344-0338-00273 [ Article] [ DOI] 10. Silva Jr SD, Zampieri TT, Ruggeri A, Ceroni A, Aragão DS, Fernandes FB, et al. Downregulation of the Vascular Renin-Angiotensin System by Aerobic Training–Focus on the Balance Between Vasoconstrictor and Vasodilator Axes. Circ J. 2015; 79(6): 1372-80. DOI: 10.1253/circj.CJ-14-1179 [ DOI] [ PubMed] 11. Seidanloo F, Farzanegi P. [Changes in Matrix Metallo-proteinases 2, 9 and Tissue Inhibitor of Matrix Metalloproteinase 1 to Synchronized Exercise Training and Celery, as an Herbal Supplement, in Overweight Women]. Pathobiol Res. 2015; 18(1): 107-118. [Article in Persian] [ View at Publisher] 12. Donley DA, Fournier SB, Reger BL, DeVallance E, Bonner DE, Olfert IM, et al. Aerobic exercise training reduces arterial stiffness in metabolic syndrome. J Appl Physiol (1985). 2014 Jun; 116(11): 1396–404. DOI: 10.1152/japplphysiol.00151.2014 [ DOI] [ PubMed] 13. Ebrahimi-Arti A, Seyedolhosseini M, Alizadeh A, Rashidlamir A, Dastani M.[Effects of 8 weeks of aerobic exercise on matrix metalloproteinase-9 and tissue inhibitor levels in type II diabetic women]. Zahedan J Res Med Sci. 2014; 16(6): 12-15. [Article in Persian] [ View at Publisher] 14. Urso ML, Pierce JR, Alemany JA, Harman EA, Nindl BC. Effects of exercise training on the matrix metalloprotease response to acute exercise. Eur J Appl Physiol. 2009 Jul; 106(5): 655-63. DOI: 10.1007/s00421-009-1063-0 [ DOI] [ PubMed] 15. Jaoude J, Koh Y. Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag. 2016 Jul; 12: 287-95. DOI: 10.2147/VHRM.S103877 [ DOI] [ PubMed] 16. Presti RL, Hopps E, Caimi G. Gelatinases and physical exercise: A systematic review of evidence from human studies. Medicine (Baltimore). 2017 Sep; 96(37): e8072. DOI: 10.1097/MD.0000000000008072 [ DOI] [ PubMed] 17. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial. Integr Blood Press Control. 2016 Jan; 9: 9-21. DOI: 10.2147/IBPC.S93335 [ DOI] [ PubMed] 18. Ginter E, Simko V. Garlic (Allium sativum L.) and cardiovascular diseases. Bratisl Lek Listy. 2010; 111(8): 452-56. [ PubMed] 19. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994 Jul; 272(2): 122-4. [ PubMed] 20. Braz NF, Carneiro MV, Oliveira-Ferreira F, Arrieiro AN, Amorim FT, Lima MM, et al. Influence of aerobic training on cardiovascular and metabolic parameters in ederly hypertensive women. Int J Prev Med. 2012 Sep; 3(9): 652-59. [ PubMed] 21. Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose–response trial. Eur J Clin Nutr. 2013 Jan; 67(1): 64-70. DOI: 10.1038/ejcn.2012.178 [ DOI] [ PubMed] 22. Bordbarazari B, Gholami M, Ebrahim K, Abed Natanzi H, Ghazalian F. The effect of endurance training along with L-arginine supplementation on the levels of MMP-2 and MMP-9 in postmenopausal hypertensive women. J Basic Res Med Sci. 2019; 6(4): 20-28. [ View at Publisher] 23. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006 Feb; 69(3): 614-24. DOI: 10.1016/j.cardiores.2005.08.002 [ DOI] [ PubMed] 24. Sugiura T, Kamioka M, Yamanaka S, Hisahara T, Hirakawa Y, Matsumura Y. Relationship between matrix metalloproteinase-3 serum level and pulmonary artery systolic pressure in patients with rheumatoid arthritis. Heart Vessels. 2018 Feb; 33(2): 191-97. DOI: 10.1007/s00380-017-1045-9 [ DOI] [ PubMed] 25. da Cunha Nascimento D, Durigan RdCM, Tibana RA, Durigan JLQ, Navalta JW, Prestes J. The response of matrix metalloproteinase-9 and-2 to exercise. Sports Med. 2015 Feb; 45(2): 269-78. DOI: 10.1007/s40279-014-0265-8 [ DOI] [ PubMed] 26. Filipović T, Gopčević K, Dimitrijević S, Hrković M, Backović A, Lazović M. Effects of 12-Week Exercise Program on Enzyme Activity of Serum Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Female Patients with Postmenopausal Osteoporosis: A Randomized Control Study. Biomed Res Int. 2020 Jan; 2020: 9758289. DOI: 10.1155/2020/9758289 [ DOI] [ PubMed] 27. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010 Jan; 1803(1): 55-71. DOI: 10.1016/j.bbamcr.2010.01.003 [ DOI] [ PubMed] 28. Martinez MLL, Lopes LF, Coelho EB, Nobre F, Rocha JBT, Gerlach RF, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan; 47(1): 117-22. DOI: 10.1097/01.fjc.0000196241.96759.71 [ DOI] [ PubMed] 29. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD (P) H oxidase–derived reactive oxygen species. Circ Res. 2003 Jun; 92(11): e80-6. DOI: 10.1161/01.RES.0000077044.60138.7C [ DOI] [ PubMed] 30. Castier Y, Brandes RP, Leseche G, Tedgui A, Lehoux S. p47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ Res. 2005 Sep; 97(6): 533-40. DOI: 10.1161/01.RES.0000181759.63239.21 [ DOI] [ PubMed] 31. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004 Mar; 49(3): 187-98. DOI: 10.1016/j.critrevonc.2003.09.008 [ DOI] [ PubMed] 32. Weiss N, Papatheodorou L, Morihara N, Hilge R, Ide N. Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. J Ethnopharmacol. 2013 Jan 9; 145(1): 162-67. DOI: 10.1016/j.jep.2012.10.045 [ DOI] [ PubMed] 33. Montezano AC, Touyz RM. Reactive oxygen species and endothelial function–role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin Pharmacol Toxicol. 2012 Jan; 110(1): 87-94. DOI: 10.1111/j.1742-7843.2011.00785.x [ DOI] [ PubMed] 34. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SAT, Ciccarelli L, et al. Matrix metalloproteinase-2 and-9 levels in obese patients. Endothelium. 2008 Jul-Aug; 15(4): 219-24. DOI: 10.1080/10623320802228815 [ DOI] [ PubMed] 35. Głowińska-Olszewska B, Urban M. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism. 2007 Jun; 56(6): 799-805. DOI: 10.1016/j.metabol.2007.01.011 [ DOI] [ PubMed] 36. Florys B, Głowińska B, Urban M, Peczyńska J. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006; 12(3): 184-89. [Article in Polish] [ PubMed] 37. Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005 Apr; 98(4): 1154-62. DOI: 10.1152/japplphysiol.00164.2004 [ DOI] [ PubMed] |
